The Filing Desk

Insight Molecular Diagnostics vs RxSight

Insight Molecular Diagnostics IMDX · RxSight RXST · Health Care Supplies

RxSight reported revenue of $134 million in fiscal 2025, 32.8 times Insight Molecular Diagnostics' $4 million in fiscal 2025. Insight Molecular Diagnostics' revenue grew 115.6% in its latest year, and RxSight's fell 3.9%. Insight Molecular Diagnostics had an operating margin of -1260.8%, against -35.8% at RxSight. Free cash flow was −$25 million at Insight Molecular Diagnostics and −$19 million at RxSight.

Side by side

Insight Molecular DiagnosticsRxSight
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$4M$134M
Revenue growth115.6%−3.9%
Revenue growth a year, last 5 years27.9%55.7%
Gross margin56.7%76.6%
Operating margin−1,260.8%−35.8%
Net margin−1,238.5%−29.0%
Free cash flow−$25M−$19M
Free cash flow margin−625.6%−14.4%
Return on capital—−82.9%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count133.2%5.1%
Last close$1.66$4.61
P/E at the last close——
Insider trades, last 12 monthsbought $11.7 million, sold $0sold $103,745
Piotroski F-score—3 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Insight Molecular DiagnosticsRxSight
Operating margin
Percent of revenue
Insight Molecular DiagnosticsRxSight
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Insight Molecular DiagnosticsRxSight

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Insight Molecular Diagnostics and RxSight pages.